Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults
NCT ID: NCT04983030
Last Updated: 2026-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
36 participants
INTERVENTIONAL
2022-04-01
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Trial of PGDM1400 and PGT121 and VRC07-523LS Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults
NCT03205917
A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment
NCT03307915
Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults
NCT02919306
A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV
NCT06812494
Safety, PK and Antiviral Activity of PGT121 Monoclonal Antibody in HIV-uninfected and HIV-infected Adults
NCT02960581
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ad26.Mos4.HIV, MVA-BN-HIV Vaccine Plus PGT121, PGDM1400, and VRC07-523LS bNAbs
Participants will receive Ad26.Mos4.HIV vaccine at week 0 and MVA-BN-HIV vaccine at week 12. The bNAbs PGT121, PGDM1400, and VRC07-523LS will be administered at week 24, and the bNAbs PGT121 and PGDM1400 will be administered at week 28.
Ad26.Mos4.HIV
Ad26.Mos4.HIV is a tetravalent vaccine containing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
MVA-BN-HIV
MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
PGT121
PGT121 is a human mAb that targets the HIV-1 V3 glycan, centered on N332.
PGDM1400
PGDM1400 is a human mAb that targets the HIV-1 V2 glycan, centered on N160.
VRC07-523LS
VRC-HIVMAB075-00-AB (VRC07-523LS) is a human monoclonal antibody (mAb) that targets the HIV-1 CD4 binding site.
Ad26.Mos4.HIV, MVA-BN-HIV Vaccine Plus Placebo
Participants will receive Ad26.Mos4.HIV vaccine at week 0 and MVA-BN-HIV vaccine at week 12. Placebo will be administered at week 24, and at week 28.
Ad26.Mos4.HIV
Ad26.Mos4.HIV is a tetravalent vaccine containing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
MVA-BN-HIV
MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
Placebo Plus PGT121, PGDM1400, and VRC07-523LS bNAbs
Participants will receive Placebo at week 0 and 12. The bNAbs PGT121, PGDM1400, and VRC07-523LS will be administered at week 24, and the bNAbs PGT121 and PGDM1400 will be administered at week 28.
PGT121
PGT121 is a human mAb that targets the HIV-1 V3 glycan, centered on N332.
PGDM1400
PGDM1400 is a human mAb that targets the HIV-1 V2 glycan, centered on N160.
VRC07-523LS
VRC-HIVMAB075-00-AB (VRC07-523LS) is a human monoclonal antibody (mAb) that targets the HIV-1 CD4 binding site.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ad26.Mos4.HIV
Ad26.Mos4.HIV is a tetravalent vaccine containing Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
MVA-BN-HIV
MVA-BN-HIV is a monovalent vaccine comprising a single Modified Vaccinia Ankara - Bavarian Nordic (MVA-BN®) vector encoding Mos1.Env, Mos2S.Env, Mos1.Gag-Pol, and Mos2.Gag-Pol HIV-1 proteins.
PGT121
PGT121 is a human mAb that targets the HIV-1 V3 glycan, centered on N332.
PGDM1400
PGDM1400 is a human mAb that targets the HIV-1 V2 glycan, centered on N160.
VRC07-523LS
VRC-HIVMAB075-00-AB (VRC07-523LS) is a human monoclonal antibody (mAb) that targets the HIV-1 CD4 binding site.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Each study participant must be willing and able to adhere to the prohibitions and restrictions specified in this protocol.
3. Study participants are ≥18 to ≤70 years old on the day of signing the ICF.
4. Each study participant must have documented HIV-1 infection.
5. Must be on suppressive ART for at least 48 weeks prior to screening. ART is defined as a combination therapy regimen including at least 2 compounds, e.g., integrase inhibitor and nucleoside reverse transcriptase inhibitors (such as DovatoTM) or more than 2 compounds, e.g., 2x nucleoside reverse transcriptase inhibitors plus integrase inhibitor.
6. Must have a plasma HIV RNA \<50 cps/mL at screening and at least 1 documented evidence of plasma HIV RNA \<50 cps/mL after the last ART change.
7. Must be willing to undergo ATI.
8. Must be medically stable as confirmed by medical history, physical examination, vital signs, and clinical laboratory tests performed at screening, and as per the investigator's discretion.
9. Ability and willingness to restart ART according to study guidelines.
10. Each study participant must meet the following laboratory criteria prior to randomization:
* Hemoglobin: Women ≥10.5 g/dL; Men ≥11.0 g/dL
* White cell count: 2,500 to 11,000 cells/mm3, inclusive
* Absolute neutrophil count: \>1,000 cells/mm3
* Platelets: 125,000 to 450,000 per mm3, inclusive
* Screening serum liver enzymes (e.g., alanine aminotransferase \[ALT\], aspartate aminotransferase \[AST\], total bilirubin): within the normal reference ranges at baseline
* Creatinine: \<1.2 x ULN
* Estimated glomerular filtration rate ≥ 60 mL/min
* CD4+: \>450 cells/mm3 at screening and at least 1 documented result \>300 cells/mm3 during 48 weeks before randomization (for nadir, see exclusion criterion 9)
* Troponin: \<1 x ULN
11. For participants who are able to become pregnant, negative serum or urine pregnancy test (with a sensitivity of 15-25 mIU/mL) within 24 hours prior to Stage 1 randomization
12. A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction starting from the first vaccination at Week 0 visit and for a period of 24 weeks after last dose of bNAb.
Exclusion Criteria
2. Anyone with contraindication to intramuscular injections, placement of intravenous lines, and blood draws eg, bleeding disorders. NOTE: nonsteroidal anti- inflammatory drugs (NSAIDS) and acetylsalicylic acid containing preparations have to be stopped for 5 days before and after planned leukapheresis.
3. Anyone with acute illness (this does not include minor illnesses such as diarrhea or mild upper respiratory tract infection) or temperature ≥38.0oC within 24 hours prior to the first dose of study vaccine; enrollment at a later date is permitted.
4. Any history of an HIV-associated malignancy (including Kaposi's sarcoma), and any type of lymphoma, or virus-associated cancers.
5. Active or recent non-HIV-associated malignancy requiring systemic chemotherapy or surgery in the 36 months prior to Stage 1 randomization or for whom such therapies are expected in the next 12 months (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy, which is considered cured with minimal risk of recurrence).
6. Anyone with a history of an underlying clinically significant acute or uncontrolled chronic medical condition or physical examination findings for which, in the opinion of the investigator, participation would not be in the best interest of the study participant.
7. History or current clinical atherosclerotic cardiovascular disease, as defined by 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines, including a previous diagnosis of any of the following:
* Acute myocardial infarction
* Acute coronary syndromes
* Stable or unstable angina
* Coronary or other arterial revascularization
* Stroke
* TIA
* Peripheral arterial disease presumed to be of atherosclerotic origin
8. Anyone with a history of HIV-related illness under CDC Category C (except for recurrent pneumonia) within 10 years prior to screening, based on available medical history and assessed by the investigator for clinical relevance.
9. Anyone with a history of repeated CD4+ \<200 cells/mm3, based on available medical history and assessed by the investigator for clinical relevance. .
10. Current receipt of ART other than nucleoside reverse transcriptase inhibitor and integrase inhibitor.
11. Anyone who had major surgery (per the investigator's judgment), within 12 weeks before dosing, or has not have fully recovered from surgery, or has surgery planned during the time the study participant is expected to participate in the study or within 6 months after the last dose of study vaccine administration.
12. Anyone with a history of myocarditis, pericarditis, cardiomyopathy, congestive heart failure with permanent sequelae, clinically significant arrhythmia (including any arrhythmia requiring medication, treatment, or clinical follow-up).
13. Anyone with an ECG with reading and showing clinically significant findings, or features that would interfere with the assessment of myocarditis/pericarditis.
14. Current advanced liver disease (non-alcoholic fatty liver disease, steatohepatitis, or alcoholic liver disease) with known or suspected cirrhosis or fibrosis score ≥F2.
15. Anyone with chronic active hepatitis B (measured by hepatitis B surface antigen test) or active hepatitis C (measured by hepatitis C virus \[HCV\] antibody test; if positive, HCV RNA polymerase chain reaction test will be used to confirm active versus past HCV infection) or syphilis infection that has not been effectively treated. Positive syphilis serology due to past effectively treated infection is not exclusionary.
16. Anyone with active, untreated gonorrhea or chlamydia infection will be referred to a clinician for appropriate treatment. If chlamydia and/or gonorrhea treatment is successfully completed, the participant is eligible for a repeat gonorrhea or chlamydia screening test and potential study entry.
17. Anyone with thyroidectomy or active thyroid disease requiring medication during the last 12 months (Not excluded: a stable thyroid supplementation).
18. Anyone with history of HIV-associated neurocognitive disease or progressive multifocal leukoencephalopathy.
19. Anyone who has had major psychiatric illness and/or drug or alcohol abuse which in the investigator's opinion would compromise the study participant's safety and/or compliance with the study procedures.
20. Anyone with a history of thrombosis with thrombocytopenia syndrome (TTS), or Heparin-induced thrombocytopenia and thrombosis syndrome (HITTS)
21. Anyone who received treatment with immunoglobulins in the 2 months or blood products in the 4 months before the planned administration of the first dose of study vaccine or has any plans to receive such treatment during the study. Prior recipients of anti-HIV bNAbs, independently of the timing, are excluded.
22. Anyone who received or plans to receive:
1. licensed live attenuated vaccines - within 28 days before or after planned administration of any of the study products.
2. other licensed (not live) vaccines - within 14 days before or after planned administration of any of the study products.
3. SARS-CoV-2 vaccines under Emergency Use Authorization (EUA) by the FDA - within 28 days before or after planned administration of any of the study products.
23. Anyone who received an investigational drug (not under EUA by the FDA) or used an invasive investigational medical device within 30 days or received an investigational vaccine within 6 months before the planned administration of the first dose of study vaccine. Receipt of prophylactic or therapeutic HIV vaccine candidate at any time is always exclusionary.
24. Anyone who is currently enrolled or plans to participate in another investigational study during the course of this study.
25. Anyone who has known allergy or history of anaphylaxis or other serious adverse reactions to vaccines or vaccine products (including any of the constituents of the study vaccines) and specifically to neomycin or streptomycin or egg products.
26. Anyone with a history of chronic urticaria (recurrent hives) or a history of chronic or recurrent eczema and/or atopic dermatitis.
27. Anyone with abnormal function of the immune system resulting from:
1. Clinical conditions (e.g., autoimmune disease or immunodeficiency that are not HIV related).
2. Chronic or recurrent use of systemic corticosteroids.
3. Administration of antineoplastic and immunomodulating agents or radiotherapy.
28. Anyone with history of acute polyneuropathy(e.g.,Guillain-Barré syndrome).
29. Anyone who cannot communicate reliably with the investigator.
30. Known resistance to 1 or more drugs in 2 or more ARV drug classes.
31. Weight \>115kg.
32. Anyone who, in the opinion of the investigator, is unlikely to adhere to the requirements of the study, or is unlikely to complete the full course of vaccination and observation.
33. Any employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator, or an employee of the sponsor (or its partners).
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen Pharmaceuticals
INDUSTRY
Harvard School of Public Health (HSPH)
OTHER
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Boris Juelg, MD PhD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Boris Juelg, MD PhD
Physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boris D Juelg, MD PHD
Role: PRINCIPAL_INVESTIGATOR
Beth Israel Deaconess Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UCLA CARE (Center for AIDs Research and Education)
Los Angeles, California, United States
Orlando Immunology Center
Orlando, Florida, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Washington University Clinical Trials Unit
St Louis, Missouri, United States
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
University of Washington Positive Research
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
38743
Identifier Type: REGISTRY
Identifier Source: secondary_id
IPCAVD014/HTX1004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.